Biotech IPOs 2026: A Candid Reality Check
LSX Congress USA
Date: September 23, 2026
Location: Boston, MA
John Rudy, Member and Co-chair of the firm's Capital Markets Practice, will participate in a panel discussion at LSX USA Congress 2026, taking place September 23-24 in Boston.
John will join industry leaders for "Biotech IPOs 2026: A Candid Reality Check," moderated by Kelly Provost of Stout Risius Ross, LLC, alongside Philip Lavin, Co-Founder of Melior Capital Management, and Richard Tannenbaum, Chief Investment Officer of OUROBOROS, to examine the realities and outlook for biotech IPOs in today's market. The discussion will explore investor appetite for biotech offerings, the milestones and proof points driving public market interest, and the strategic considerations companies face when evaluating IPO, private financing, and M&A pathways.
As life sciences companies continue to navigate evolving capital markets conditions, the panel will provide practical insights for management teams, investors, and industry stakeholders assessing financing and growth strategies.
For more information about the conference, visit the LSX USA Congress agenda.
Speakers
